Keywords: مهارکننده های PCSK9; Ezetimibe; PCSK9 inhibitors; Lipid-lowering therapy; Atherosclerosis; Plaque regression; ACS; acute coronary syndrome; ASCVD; atherosclerotic cardiovascular disease; CuVIC; Effect of Cholesterol Absorption Inhibitor Usage on Target Vessel Dysfunction Afte
مقالات ISI مهارکننده های PCSK9 (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: مهارکننده های PCSK9; Antisense oligonucleotides; PCSK9 inhibitors; Apolipoprotein CIII inhibitors; CETP inhibitors; Lp(a);
Keywords: مهارکننده های PCSK9; Acute coronary syndrome; Dyslipidemia; Statin; Ezetimibe; PCSK9 inhibitors;
Keywords: مهارکننده های PCSK9; Statins; Statin intolerance; Myopathy; Ezetimibe; Bile acid sequestrants; PCSK9 inhibitors; Lipoprotein apheresis;
Keywords: مهارکننده های PCSK9; Homozygous familial hypercholesterolemia; Cardiovascular disease; HoFH; PCSK9 inhibitors; LDL-C;
Keywords: مهارکننده های PCSK9; Lipids and ischemic heart disease; PCSK9 inhibitors; Consensus document; LÃpidos en enfermedad coronaria; Inhibidores PCSK9; Documento de consenso; ACS; acute coronary syndrome; FH; familial hypercholesterolemia; LDL; low-density lipoproteins; LDLc; low-
Keywords: مهارکننده های PCSK9; Statins; Myopathy; Coenzyme Q10; Pharmacogenetics; Physiogenomics; Myalgia; Lipid metabolism; PCSK9 inhibitors;
Keywords: مهارکننده های PCSK9; Statin intolerance; Myalgias; Myopathy; PCSK9 inhibitors; ACC/AHA; American College of Cardiology/American Heart Association; ASCVD; Atherosclerotic cardiovascular disease; CoQ10; Coenzyme Q 10; CK; Creatine Kinase; FDA; Federal Drug Administration; HMG-C
Keywords: مهارکننده های PCSK9; cholesterol absorption inhibitors; low-density lipoprotein cholesterol; macrovascular disease; PCSK9 inhibitors; statinsinhibiteurs de l'absorption du cholestérol; cholestérol à lipoprotéines de faible densité; maladie macrovasculaire; inhibiteurs de PCSK
Keywords: مهارکننده های PCSK9; LDL cholesterol; Apo B antisense; MTP inhibitors; PCSK9 inhibitors;
Keywords: مهارکننده های PCSK9; PCSK9 inhibitors; Familial hypercholesterolemia; Cardiovascular events
Case reports of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition nonresponse
Keywords: مهارکننده های PCSK9; Coronary artery disease; Cardiovascular diseases; Dyslipidemia; Hypercholesterolemia; PCSK9 inhibitors;
The cost-effectiveness of PCSK9 inhibitors - The Australian healthcare perspective
Keywords: مهارکننده های PCSK9; Cost-effectiveness; PCSK9 inhibitors; Lipids; Cardiovascular disease; Prevention;
PCSK9 inhibitors in clinical practice: Delivering on the promise?
Keywords: مهارکننده های PCSK9; PCSK9 inhibitors; Familial hypercholesterolemia; Statin intolerance; Hypercholesterolemia; Lipid-lowering drugs;
LDL-cholesterol target achievement in patients with heterozygous familial hypercholesterolemia at Groote Schuur Hospital: Minority at target despite large reductions in LDL-C
Keywords: مهارکننده های PCSK9; Heterozygous familial hypercholesterolemia; LDL-Cholesterol; Target achievement; Cardiovascular disease; Statins; Ezetimibe; PCSK9 inhibitors;
Niveles óptimos de colesterol en los pacientes con dislipemia. Revisión sistemática de la evidencia
Keywords: مهارکننده های PCSK9; Colesterol; Estatina; Ezetimiba; Inhibidores PCSK9; Cholesterol; Statin; Ezetimibe; PCSK9 inhibitors;
PCSK9 and neurocognitive function: Should it be still an issue after FOURIER and EBBINGHAUS results?
Keywords: مهارکننده های PCSK9; Brain; Cholesterol; Cholesterol-lowering treatment; Neurocognitive function; PCSK9; PCSK9 inhibitors;
Clinical and pathophysiological evidence supporting the safety of extremely low LDL levels-The zero-LDL hypothesis
Keywords: مهارکننده های PCSK9; Low-LDL; PCSK9 inhibitors; Ezetimibe; Lipid-lowering therapy; Low-LDL safety;
Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitor use in the management of resistant hypercholesterolemia induced by mitotane treatment for adrenocortical cancer
Keywords: مهارکننده های PCSK9; Mitotane; Adrenocortical carcinoma; ACC; Hypercholesterolemia; PCSK9 inhibitors; PCSK9; Evolocumab;
Estudios clÃnicos con inhibidores de la PCSK9
Keywords: مهارکننده های PCSK9; iPCSK9; Prevención secundaria; Hipercolesterolemia familiar; Intolerancia a estatinas; PCSK9 inhibitors; Secondary prevention; Familial hypercholesterolemia; Statin intolerance;
Barriers to PCSK9 inhibitor prescriptions for patients with high cardiovascular risk: Results of a healthcare provider survey conducted by the National Lipid Association
Keywords: مهارکننده های PCSK9; PCSK9 inhibitors; Statins; Dyslipidemia; Familial hypercholesterolemia; Practice patterns;
Heterozygous familial hypercholesterolemia presenting as chylomicronemia syndrome
Keywords: مهارکننده های PCSK9; Chylomicronemia syndrome; Heterozygous familial hypercholesterolemia; Genetics; Triglyceride rich lipoproteins; PCSK9 inhibitors;
Update on the use of PCSK9 inhibitors in adults: Recommendations from an Expert Panel of the National Lipid Association
Keywords: مهارکننده های PCSK9; PCSK9 inhibitors; Evolocumab; Alirocumab; Dyslipidemia; Hypercholesterolemia; Familial hypercholesterolemia; Statin intolerance; Lipid treatment guidelines;
Cost-effectiveness of Evolocumab in Patients With High Cardiovascular Risk in Spain
Keywords: مهارکننده های PCSK9; cardiovascular disease; cost-effectiveness; evolocumab; hypercholesterolemia; LDL-C; PCSK9 inhibitors;
Proprotein convertase subtilisin/kexin 9Â inhibition in patients with familial hypercholesterolemia: Initial clinical experience
Keywords: مهارکننده های PCSK9; Cardiovascular disease; Familial hypercholesterolemia; PCSK9 inhibitors; Lipid-lowering therapy; Side effects; Injection site reaction;
PCSK9 Monoclonal Antibodies in 2016: Current Status and Future Challenges
Keywords: مهارکننده های PCSK9; PCSK9 inhibitors; Statins; Lipid lowering therapies; LDL-C; Low-density lipoprotein cholesterol; LDL-R; Low-density lipoprotein receptor; PCSK9; Proprotein Convertase Subtilisin/Kexin type 9; ACS; Acute coronary syndrome; FDA; Food and Drug Administration
2017 Focused Update of the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk
Keywords: مهارکننده های PCSK9; ACC Expert Consensus Decision Pathway; ASCVD; bile acid sequestrants; cholesterol; dyslipidemia; ezetimibe; LDL-C; lipids; PCSK9 inhibitors; statins;
Old challenges and new opportunities in the clinical management of heterozygous familial hypercholesterolemia (HeFH): The promises of PCSK9 inhibitors
Keywords: مهارکننده های PCSK9; Heterozygous familial hypercholesterolemia; Low-density lipoprotein cholesterol; Cardiovascular risk; PCSK9 inhibitors; Alirocumab; Evolocumab;
Proprotein convertase subtilisin kexin 9 (PCSK9) inhibitors to treat hypercholesterolemia: Effect on stroke risk
Keywords: مهارکننده های PCSK9; Alirocumab; Evolocumab; Ischemic stroke; Lipid lowering; Hypercholesterolemia; PCSK9 inhibitors;
Transition from LDL apheresis to evolocumab in heterozygous FH is equally effective in lowering LDL, without lowering HDL cholesterol
Keywords: مهارکننده های PCSK9; Familial hypercholesterolemia; LDL-apheresis; PCSK9 inhibitors;
Necesidades no cubiertas con el tratamiento hipolipemiante oral: documento de posición de la Sociedad Española de CardiologÃa
Keywords: مهارکننده های PCSK9; LÃpidos en enfermedad coronaria; Inhibidores PCSK9; Documento de consenso; Lipids and ischemic heart disease; PCSK9 inhibitors; Consensus document; cLDL; colesterol unido a lipoproteÃnas de baja densidad; HF; hipercolesterolemia familiar; LDL; lipoprote
Determining When to Add Nonstatin Therapy
Keywords: مهارکننده های PCSK9; cost; ezetimibe; nonstatins; PCSK9 inhibitors; statins; ARR; absolute risk reduction; ASCVD; atherosclerotic cardiovascular disease; FH; familial hypercholesterolemia; ICER; Institute for Clinical and Economic Review; LDL-C; low-density lipoprotein choles
2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk
Keywords: مهارکننده های PCSK9; ACC Expert Consensus Decision Pathway; ASCVD; bile acid sequestrants; cholesterol; dyslipidemia; ezetimibe; LDL-C; lipids; PCSK9 inhibitors; statins;
LDL-R promoting activity of peptides derived from human PCSK9 catalytic domain (153–421): Design, synthesis and biochemical evaluation
Keywords: مهارکننده های PCSK9; Proprotein Convertase Subtilisin Kexin 9 (PCSK9); Low Density Lipoprotein receptor (LDL-R); Cholesterol lowering agents; PCSK9 inhibitors; Epidermal Growth Factor-A (EGF-A); Fluorescence quenchingAa, Amino acid; ACN, Acetonitrile; BSA, Bovine serum albumi
Non-statin Treatments for Managing LDL Cholesterol and Their Outcomes
Keywords: مهارکننده های PCSK9; CETP inhibitors; LDL cholesterol; PCSK9 inhibitors; Familial hypercholesterolemia;
Targeting LDL: Is lower better and is it safe?
Keywords: مهارکننده های PCSK9; LDL cholesterol; Friedewald formula; statins; PCSK9 inhibitors
Lipoprotein apheresis: State of the art and novelties
Keywords: مهارکننده های PCSK9; Lipoprotein apheresis; Severe hypercholesterolemia; Pediatric treatment; Lomitapide; PCSK9 inhibitors; Mipomersen; HDL-enhancers; Lipoprotein apheresis in pregnancy
Other Therapies for Reducing Low-Density Lipoprotein Cholesterol: Medications in Development
Keywords: مهارکننده های PCSK9; LDL cholesterol; Apo B antisense; MTP inhibitors; Squalene synthase inhibitors; PCSK9 inhibitors;